<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880720</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0454</org_study_id>
    <nct_id>NCT04880720</nct_id>
  </id_info>
  <brief_title>Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients</brief_title>
  <acronym>SENO-COVID</acronym>
  <official_title>Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune aging or immunosenescence is characterized by a loss of T cell clonal diversity and a&#xD;
      contraction of naïve T cells with proliferative capacity associated with the functional&#xD;
      impairment of many others immune cells as well as a chronic low degree of inflammation. A&#xD;
      restrictive T cell repertoire is likely more prone to antigen-mediated exhaustion observed&#xD;
      during chronic viral infections. Notably, lymphopenia is the most consistent laboratory&#xD;
      abnormality in COVID-19 infected patients and both lung-resident and circulating T cells&#xD;
      potently up-regulate markers of T cell exhaustion. It is not clear today if the association&#xD;
      of COVID-19 disease severity with age is mainly related with the immunosenescence of infected&#xD;
      patients. Interestingly, T cell exhaustion and premature immunosenescence have also been&#xD;
      observed in chronic inflammatory diseases such as rheumatoid arthritis (RA). To better&#xD;
      understand the immunological mechanisms involved in SARS-Cov-2 pathophysiology, the&#xD;
      investigators propose to compare the immunosenescence patterns observed during RA, aging and&#xD;
      SARS-Cov-2 infected patients in order to design improved therapeutic interventions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Results of phenotypic immunosenescence analyses of COVID-19 patients targeting 5 different immune populations (neutrophils, T lymphocytes, NK lymphocytes, B lymphocytes and monocytes).</measure>
    <time_frame>At inclusion visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of previous results with the results of senescence immunophenotyping in peripheral blood of a reference population with an inflammatory disease (active RA)</measure>
    <time_frame>At inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of previous results with the results of senescence immunophenotyping in peripheral blood of a reference population of healthy controls.</measure>
    <time_frame>At inclusion visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of a specific gene expression of immunosenescence induced in COVID-19 patients, using transcriptomic analysis in the different immune subpopulations previously identified and specific to COVID-19 patients.</measure>
    <time_frame>At inclusion visit</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>SARS-Cov-2 Infection</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>COVID-19 Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Comparator</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling - 10mL</description>
    <arm_group_label>COVID-19 Patients</arm_group_label>
    <arm_group_label>Healthy Comparator</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  COVID-19 patients are recruited through the Covidothèque project and the UANDES center&#xD;
             (Chile)&#xD;
&#xD;
          -  RA patients and healthy subjects are recruited through 3 rheumatology reference&#xD;
             centers (Montpellier, Paris Saint-Antoine and Saint-Etienne)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Active RA Patients:&#xD;
&#xD;
          -  Patients with rheumatoid arthritis (RA) meeting the 2010 ACR/EULAR diagnostic criteria&#xD;
&#xD;
          -  Patients in inflammatory flare of RA (DAS28 &gt; 3.2)&#xD;
&#xD;
          -  Patients who have been off biological disease-modifying antirheumatic drugs (bDMARDs)&#xD;
             or targeted synthetic antirheumatic drugs (tsDMARDs) for RA for at least 2 weeks&#xD;
             (except for rituximab, where a delay of at least 12 months is required)&#xD;
&#xD;
          -  Conventional synthetic DMARDs (Methotrexate, Hydroxychloroquine, Leflunomide,&#xD;
             Sulfasalazine) are allowed&#xD;
&#xD;
          -  Beneficiary of a social security system&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Inclusion Criteria for Healthy Controls:&#xD;
&#xD;
          -  Absence of chronic diseases and current infection&#xD;
&#xD;
          -  Beneficiary of a social security system&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Inclusion Criteria for COVID-19+ Patients:&#xD;
&#xD;
          -  Patients with ongoing SARS-Cov-2 infection (PCR+)&#xD;
&#xD;
          -  Patients hospitalized at D7-D14 of symptoms onset&#xD;
&#xD;
          -  Patients with two or more SARS-Cov-2 symptoms (including fever, cough, dyspnea, sore&#xD;
             throat, chest pain, anosmia, diarrhea)&#xD;
&#xD;
          -  Membership in or beneficiary of a social security scheme&#xD;
&#xD;
          -  Collection of free and informed consent&#xD;
&#xD;
        Exclusion Criteria for All Groups:&#xD;
&#xD;
          -  Subjects under 18 years of age&#xD;
&#xD;
          -  HIV positive patients&#xD;
&#xD;
          -  Diabetic patients&#xD;
&#xD;
          -  Morbidly obese patients (BMI &gt; 40kg/m2)&#xD;
&#xD;
          -  Use of senolytic drugs in the week prior to inclusion (azithromycin, metformin,&#xD;
             cyclosporine, JAK inhibitors)&#xD;
&#xD;
          -  Use of steroids in doses greater than 10 mg/day in the week prior to inclusion&#xD;
&#xD;
          -  Subjects unable to give consent&#xD;
&#xD;
          -  Pregnant, breastfeeding, or non-menopausal women not taking effective contraception&#xD;
&#xD;
          -  Vulnerable subjects protected by law&#xD;
&#xD;
          -  Subjects under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YVES MARIE PERS</last_name>
    <phone>04 67 33 90 84</phone>
    <email>ym-pers@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34080</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SOPHIE GRASSET</last_name>
      <phone>04 67 33 90 84</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Wang R, Pan M, Zhang X, Han M, Fan X, Zhao F, Miao M, Xu J, Guan M, Deng X, Chen X, Shen L. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis. 2020 Jun;95:421-428. doi: 10.1016/j.ijid.2020.03.070. Epub 2020 Apr 11.</citation>
    <PMID>32289565</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.</citation>
    <PMID>32294485</PMID>
  </reference>
  <reference>
    <citation>Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol. 2009 Jul;83(14):7062-74. doi: 10.1128/JVI.00127-09. Epub 2009 May 6. Erratum in: J Virol. 2009 Sep;83(17):9022.</citation>
    <PMID>19420084</PMID>
  </reference>
  <reference>
    <citation>Maringer K, Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine Growth Factor Rev. 2014 Dec;25(6):669-79. doi: 10.1016/j.cytogfr.2014.08.004. Epub 2014 Aug 24. Review.</citation>
    <PMID>25212897</PMID>
  </reference>
  <reference>
    <citation>Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018 Jan;19(1):10-19. doi: 10.1038/s41590-017-0006-x. Epub 2017 Dec 14. Review. Erratum in: Nat Immunol. 2018 Oct;19(10):1146.</citation>
    <PMID>29242543</PMID>
  </reference>
  <reference>
    <citation>Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. doi: 10.3389/fimmu.2017.01960. eCollection 2017. Review.</citation>
    <PMID>29375577</PMID>
  </reference>
  <reference>
    <citation>Tachikart Y, Malaise O, Mumme M, Jorgensen C, Brondello JM. Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases. Biochem Pharmacol. 2019 Jul;165:126-133. doi: 10.1016/j.bcp.2019.03.017. Epub 2019 Mar 13. Review.</citation>
    <PMID>30878551</PMID>
  </reference>
  <reference>
    <citation>Oh SJ, Lee JK, Shin OS. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Netw. 2019 Nov 14;19(6):e37. doi: 10.4110/in.2019.19.e37. eCollection 2019 Dec. Review.</citation>
    <PMID>31921467</PMID>
  </reference>
  <reference>
    <citation>Vicente R, Mausset-Bonnefont AL, Jorgensen C, Louis-Plence P, Brondello JM. Cellular senescence impact on immune cell fate and function. Aging Cell. 2016 Jun;15(3):400-6. doi: 10.1111/acel.12455. Epub 2016 Feb 22. Review.</citation>
    <PMID>26910559</PMID>
  </reference>
  <reference>
    <citation>Campos C, Pera A, Sanchez-Correa B, Alonso C, Lopez-Fernandez I, Morgado S, Tarazona R, Solana R. Effect of age and CMV on NK cell subpopulations. Exp Gerontol. 2014 Jun;54:130-7. doi: 10.1016/j.exger.2014.01.008. Epub 2014 Jan 17.</citation>
    <PMID>24440462</PMID>
  </reference>
  <reference>
    <citation>Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol. 2007 May;42(5):432-7. Epub 2007 Jan 8. Review.</citation>
    <PMID>17307327</PMID>
  </reference>
  <reference>
    <citation>Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007 May;42(5):400-6. Epub 2007 Jan 10. Review.</citation>
    <PMID>17218073</PMID>
  </reference>
  <reference>
    <citation>Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732. doi: 10.1080/22221751.2020.1746199.</citation>
    <PMID>32196410</PMID>
  </reference>
  <reference>
    <citation>de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27. Review.</citation>
    <PMID>27344959</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>D'Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020 Jun;26(6):832-834. doi: 10.1002/lt.25756. Epub 2020 Apr 24.</citation>
    <PMID>32196933</PMID>
  </reference>
  <reference>
    <citation>Giacalone VD, Margaroli C, Mall MA, Tirouvanziam R. Neutrophil Adaptations upon Recruitment to the Lung: New Concepts and Implications for Homeostasis and Disease. Int J Mol Sci. 2020 Jan 28;21(3). pii: E851. doi: 10.3390/ijms21030851. Review.</citation>
    <PMID>32013006</PMID>
  </reference>
  <reference>
    <citation>Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010 Oct;11(10):889-96. doi: 10.1038/ni.1937. Epub 2010 Sep 20. Review.</citation>
    <PMID>20856220</PMID>
  </reference>
  <reference>
    <citation>Nicolás-Ávila JÁ, Adrover JM, Hidalgo A. Neutrophils in Homeostasis, Immunity, and Cancer. Immunity. 2017 Jan 17;46(1):15-28. doi: 10.1016/j.immuni.2016.12.012. Review.</citation>
    <PMID>28099862</PMID>
  </reference>
  <reference>
    <citation>Cloke T, Munder M, Bergin P, Herath S, Modolell M, Taylor G, Müller I, Kropf P. Phenotypic alteration of neutrophils in the blood of HIV seropositive patients. PLoS One. 2013 Sep 9;8(9):e72034. doi: 10.1371/journal.pone.0072034. eCollection 2013.</citation>
    <PMID>24039734</PMID>
  </reference>
  <reference>
    <citation>Bowers NL, Helton ES, Huijbregts RP, Goepfert PA, Heath SL, Hel Z. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog. 2014 Mar 13;10(3):e1003993. doi: 10.1371/journal.ppat.1003993. eCollection 2014 Mar.</citation>
    <PMID>24626392</PMID>
  </reference>
  <reference>
    <citation>Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5. Review.</citation>
    <PMID>32282863</PMID>
  </reference>
  <reference>
    <citation>Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.</citation>
    <PMID>32161940</PMID>
  </reference>
  <reference>
    <citation>Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.</citation>
    <PMID>32203188</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

